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Purpose: A DCE- MRI technique that can provide both high spatiotemporal resolu-
tion and whole- brain coverage for quantitative microvascular analysis is highly de-
sirable but currently challenging to achieve. In this study, we sought to develop and 
validate a novel dual- temporal resolution (DTR) DCE- MRI- based methodology for 
deriving accurate, whole- brain high- spatial resolution microvascular parameters.
Methods: Dual injection DTR DCE- MRI was performed and composite high- 
temporal and high- spatial resolution tissue gadolinium- based- contrast agent (GBCA) 
concentration curves were constructed. The high- temporal but low- spatial resolu-
tion first- pass GBCA concentration curves were then reconstructed pixel- by- pixel to 
higher spatial resolution using a process we call LEGATOS. The accuracy of kinetic 
parameters (Ktrans, vp, and ve) derived using LEGATOS was evaluated through simu-
lations and in vivo studies in 17 patients with vestibular schwannoma (VS) and 13 
patients with glioblastoma (GBM). Tissue from 15 tumors (VS) was examined with 
markers for microvessels (CD31) and cell density (hematoxylin and eosin [H&E]).
Results: LEGATOS derived parameter maps offered superior spatial resolution 
and improved parameter accuracy compared to the use of high- temporal resolution 
data alone, provided superior discrimination of plasma volume and vascular leakage 
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1 |  INTRODUCTION
Kinetic parameters derived from DCE- MRI are increasingly 
used in the study of tumors, both within and outside the brain, 
for assessment of tumor microenvironment and microvascu-
lature. They have demonstrable value as predictive, prognos-
tic, and treatment response biomarkers and are of increasing 
importance with the growing use of anti- angiogenic thera-
pies.1- 7 Key limitations in current DCE- MRI techniques in-
clude the volume coverage, spatial resolution and accuracy of 
derived kinetic parameters, and the requirement for full- dose 
gadolinium- based- contrast agent (GBCA) administration 
during data acquisition.8- 13 Whereas whole- brain coverage 
and high- spatial (HS) resolution are essential where lesions 
are widespread, small, or exhibit significant microvascular 
heterogeneity, high- temporal (HT) resolution is required for 
accurate quantification of kinetic parameters such as cerebral 
blood flow, fractional plasma volume (vp), transfer constant 
(Ktrans), and the fractional volume of extravascular extracel-
lular space (ve).
14- 16
Traditional Cartesian MRI has limitations in achieving 
simultaneous HS and HT resolution so that a compromise 
must be made in the protocol design. Dual- temporal resolu-
tion (DTR) techniques incorporating a staged dual- bolus of 
GBCA have been developed to address this limitation.17 Li 
and colleagues measured plasma concentration curves from 
an initial low- dose high- temporal (LDHT) resolution acqui-
sition to reconstruct a HT resolution vascular input function 
(VIF).18 This accurate VIF was then used for subsequent ki-
netic analysis of a second full- dose HS resolution (FDHS) 
data set. This approach, termed the dual injection contrast 
enhanced (DICE)- FDHS method, generated HS resolution 
parametric maps, however, the low- temporal resolution 
(frame duration ∆t = 10 s) of the GBCA uptake curves in 
tissue resulted in covariate errors during kinetic fitting, ob-
servable as large vessel and vascular leakage contamination 
within the derived Ktrans and vp maps, respectively.
17
DTR DCE- MRI methods that can provide accurate phar-
macokinetic estimates with high spatiotemporal resolution 
are, therefore, needed. Both dual injection and a single low- 
dose injection DTR DCE- MRI have shown the potential to 
provide high spatiotemporal resolution and whole- brain 
coverage for quantitative microvascular analysis.19- 21 This 
paper focuses on the dual injection technique. The aims 
of this feasibility study are therefore (1) to develop a new 
analysis technique, the level and rescale the gadolinium con-
trast concentration curves of high- temporal to high- spatial 
(LEGATOS) method, for deriving accurate, whole- brain 
high- spatial resolution microvascular parameters from dual 
injection DTR DCE- MRI data, and (2) to validate parameter 
estimates derived using the LEGATOS method using both 
computer simulation and an in vivo study incorporating cor-
relation with histopathological data.
2 |  METHODS
2.1 | Patients
For this feasibility study, we investigated previously ac-
quired dual injection DTR DCE- MRI data in 13 patients with 
glioblastoma (GBM) and 17 patients with vestibular schwan-
noma (VS) (including 1 patient with bilateral neurofibroma-
tosis type 2 [NF2]- related VS). Although GBM are the most 
common malignant brain tumor in adults, VS were also cho-
sen as a disease model because they are not influenced by 
brain microenvironment and its vasculature because of their 
extra- axial location. In addition, smaller tumors can be re-
sected whole permitting more robust comparisons between 
imaging and tissue data. The study obtained ethical approval 
(NHS Health Research Authority; NRES committee North 
West 13/NW/0131 and 13/NW/0247), and all participants 
provided informed consent.
2.2 | MR imaging
Imaging was performed on 2 Philips Achieva whole body 
scanners (Philips, Best, Netherlands) with most patients 
scanned at 1.5T (1 patient with a sporadic VS was scanned at 
3.0T). For all studie, a macrocyclic GBCA (gadoterate meg-
lumine; Dotarem, Guerbet S.A.) was administered by power 
injector as an intravenous bolus at a rate of 3 mL/s, followed 
by a chaser of 20 mL of 0.9% saline administered at the same 
effects compared to other high- spatial resolution approaches, and correlated with tis-
sue markers of vascularity (P ≤ 0.003) and cell density (P ≤ 0.006).
Conclusion: The LEGATOS method can be used to generate accurate, high- spatial 
resolution microvascular parameter estimates from DCE- MRI.
K E Y W O R D S
accurate kinetic parameter mapping, dual- temporal resolution DCE- MRI, perfusion and 
permeability, spatial and temporal resolution
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rate. High- resolution 3D T1- weighted (T1W) gradient echo 
sequence with whole- brain coverage (TE = 3.2 ms, TR = 
8.6 ms, slice thickness = 1.2 mm) both before and after con-
trast were obtained for tumor delineation.
Data were acquired using a previously described DTR, 
DICE technique.17 For the first part of this DTR technique, a 
low- dose fixed- volume of GBCA was administered during ac-
quisition of a HT resolution sequence using a 3D gradient echo 
sequence with a flip angle of 20°, TR/TE of 2.5 ms/0.696 ms, 
SENSE acceleration factor of 1.8, reconstructed matrix 
size of 96 × 96 × 22, voxel size of 2.5 × 2.5 × 6.35 mm3, 
pixel bandwidth of 700 Hz, and frame duration (Δt) of 1.0 s 
(n = 300). This was followed by a full- dose of GBCA (dose = 
0.2 mL/kg × weight − dose of prebolus) administered during 
acquisition of a HS resolution sequence with a flip angle of 
20°, TR/TE of 3.7 ms/0.93 ms, SENSE acceleration factor 
of 2.8, reconstructed matrix size of 240 × 240 × 70, recon-
structed voxel size of 1 × 1 × 2 mm3, pixel bandwidth of 
700 Hz, and frame duration (Δt) of 10.7 s (n = 60). For both 
the LDHT and FDHS acquisition, 0 padding was used for 
FFT reconstruction in the z- direction, which doubles the 
number of slices. For baseline longitudinal relaxation rate 
(R10) mapping, variable flip- angle (VFA; α = 2°, 8°, 15°, and 
20°) acquisitions were undertaken before both the LDHT and 
FDHS DCE series. The spatial resolution of each VFA acqui-
sition series was chosen to match the LDHT (2.5 × 2.5 × 6.35 
mm3) and FDHS (1 × 1 × 2 mm3) DCE series, respectively.
2.3 | The new DTR DCE- MRI 
processing method
Our new DTR- based mapping technique relied on 2 key 
steps, which can be summarized as follows:
Key step I: combination of the HT and HS res-
olution series to construct a 4D GBCA con-
centration volume (HTHS- merged) with a HT 
arterial phase followed by a HS parenchymal 
tissue phase.
A 2- part 4D GBCA concentration volume, termed HTHS- 
merged, was constructed from the HT (high- temporal, low- 
spatial) and HS (high- spatial, low- temporal) resolution dynamic 
series. The native 4D HT dynamic images (voxel size = 2.5 × 
2.5 × 6.35 mm3) were first co- registered and resliced to a HS 
baseline image frame (voxel size = 1 × 1 × 2 mm3) using a 
4th degree B- spline interpolation within statistical parametric 
mapping22 to obtain a 4D HTaligned volume (voxel size = 1 × 1 × 
2 mm3). The signal intensity- time curves from this 4D HTaligned 
and the 4D HS dynamic image volumes were then converted to 
GBCA concentration- time curves using their respective base-
lines and R10 derived from the pre- injection VFA acquisitions.
The constructed DTR 4D GBCA concentration volume 
(HTHS- merged) must retain an HT arterial phase to en-
able accurate discrimination between plasma volume and 
vascular leakage effects. The initial 40 s of the HTaligned 
concentration- time course was, therefore, concatenated with 
later concentration- time points obtained from the FDHS se-
ries. The time point for this adjoining (tadj) was selected to be 
just after the recirculation phase to limit the effects of rapid 
systemic contrast agent leakage and fluctuations because of 
recirculation. Because of the differences in administered dose 
and time of GBCA administration between the LDHT and 
FDHS DCE series, the later phase of the HS concentration 
curves also needed to be cross- calibrated with the HT curves 
for both bolus arrival time (BAT) and GBCA dose before 
concatenation.19
The major steps in the construction of the DTR 4D con-
centration volume from the dual injection DTR data are illus-
trated in Figure 1.
Key step II: pixel- by- pixel rescaling the concat-
enated HT arterial phase to resemble the sup-
posed “true” HS resolution arterial phase using 
LEGATOS.
Through containing an initial HT arterial phase (HTaligned) 
followed by a HS parenchymal tissue phase, the HTHS- 
merged volume maintains the temporal fidelity of the arte-
rial phase of the LDHT series. Despite the HT data set being 
resampled/interpolated in image space to higher spatial res-
olution, however, the observed HTaligned data (voxel size = 
1 × 1 × 2 mm3) still primarily reflects the arterial phase of 
the acquired low- spatial resolution pixel GBCA concentra-
tion curve and must be replaced with a reconstructed HS 
arterial phase. Without this reconstruction step parameter 
maps (in particular vp) derived from kinetic fitting of the 4D 
HTHS- merged concentration volume generated in key step I 
would still closely resemble those obtained from the native 
low- spatial resolution LDHT DCE data set.
In key step II, LEGATOS was therefore used for pixel- 
by- pixel reconstruction of the concatenated low- spatial reso-
lution HT arterial phase of the HTHS- merged concentration 
volume to reflect the supposed “true” HS resolution one. This 
pixel- wise reconstruction method was based on the fact that 
the GBCA concentration value is not affected by the imag-
ing parameters. Rather, the observed difference in the GBCA 
concentration between the concatenated HTaligned and dose- 
adjusted HS concentration curves in each pixel of the HTHS- 
merged 4D concentration volume (Figure 2, left column, voxel 
size = 1 × 1 × 2 mm3) reflects the difference in the native 
spatial resolution during data acquisition and any possible ef-
fects of the statistical parametric mapping interpolation of the 
native HT arterial phase; assuming there is no dominant noise 
process affecting estimated GBCA concentration. In addition, 
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the LEGATOS method assumes that in each tissue pixel of 
the HTHS- merged 4D concentration volume generated in key 
step I, the supposed “true” HS resolution arterial phase has the 
same shape as the observed HTaligned arterial phase, so it can 
be obtained by re- scaling the HTaligned arterial phase using a 
calibration ratio, ratiocalib. Therefore,
where Ct- HT(t) is the observed HTaligned arterial phase 
concentration- time curve, Ct- HS(t) is the supposed “true” HS 
arterial phase concentration- time curve, and
The calibration ratio was calculated from the concate-
nated HTHS- merged concentration- time curve by taking the 
ratio of the mean concentration of 5 HS frames following 
the concatenation time point, tadj, over the mean concentra-
tion of 4 final frames of the HTaligned arterial phase series 
before tadj. This calibration ratio was then used to rescale the 
initial HTaligned arterial phase of each pixel concentration- 
time curve to achieve a smooth concatenation with the later 
HS parenchymal phase before kinetic fitting (Figure 2). The 
LEGATOS method will automatically adjust this calibration 
ratio and scaling procedure to achieve a smooth concatena-
tion between the HTaligned and HS concentration- time curves. 
As such, although the first- pass bolus shape of the HTaligned 
curve is propagated through to the reconstructed arterial 
phase of the HS curve, any scale change (eg, because of sta-
tistical parametric mapping interpolation) of the HTaligned 
arterial phase will not be propagated through to the final 
concentration- time curve.
2.4 | Kinetic analysis
The extended Tofts model (ETM) was fitted to the tissue 
GBCA concentration- time curves of the 4D HTHS- merged 
concentration volume from each patient.23,24 This fitting was 










F I G U R E  1  Combination of the low- dose high- temporal (LDHT) and full- dose high- spatial (FDHS) data from dual injection DTR MRI. 
Combination of the low- dose high- temporal (LDHT) and full- dose high- spatial (FDHS) GBCA concentration- time curves from dual injection dual- 
temporal resolution DCE MRI data are shown. The LDHT data are first co- registered to a HS baseline image frame and interpolated to generate 
a 4D HTaligned DCE data set with the same x, y, and z dimensions (1 × 1 × 2 mm
3) as each HS image frame. To allow for timing cross- calibration 
in the subsequent merge process, the arterial input function bolus arrival time (BATAIF) and the time point for adjoining the HTaligned and FDHS 
concentration- time curves (tadj) are derived for the LDHT and FDHS data sets, respectively. The 4D HTaligned and FDHS signal intensity (SI) DCE 
volumes are then converted to 4D GBCA concentration volumes. For the merge process the later parenchymal phase of the FDHS concentration- 
time curves are cross- calibrated with the LDHT curves for both timing and GBCA dose and are then concatenated to the arterial phase of the low- 
dose HTaligned data set to generate a HTHS- merged 4D concentration volume. GBCA = gadolinium- based- contrast agent
Baseline
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high temporal, low spatial resolution
(LDHT) DCE SI volume to a high
spatial resolution (HS) baseline image
frame to produce 4D HTaligned data.
Preparation prior to merge
2. Measure BATAIF for 4D HTaligned and 4D
full dose high spatial, low temporal
resolution (FDHS) DCE volume respectively.
Calculate tadj for HTaligned and FDHS DCE
curves by:
tadj-HT = BATAIF-HT + 40 s
tadj-HS = BATAIF-HS + 40 s
3. Convert 4D HTaligned and FDHS
DCE SI volume to 4D GBCA
concentration ([GBCA]) volume.
Merge HTaligned and FDHS DCE  [GBCA] volume
4. The later parenchymal
phase of the HS GBCA
concentration-time curves are
cross-calibrated with the HT
curves for both BAT and dose,
and then concatenated to the
HTaligned arterial phase.
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performed either immediately following key step I (HTHS- 
merged method), or following both key steps I and II above 
(the LEGATOS method). In both cases the final spatial 
resolution of derived kinetic parameter maps was 1 × 1 × 2 
mm. Kinetic analysis was also performed using the LDHT 
or FDHS tissue GBCA concentration- time curves alone as 
a comparative measure. The dynamic MR signal measured 
from voxels in the vertical part of superior sagittal sinus was 
used as an indirect estimate of the arterial input function as 
described previously25,26 (Supporting information Figure 
S1). As part of the fitting procedure the BAT for each tissue 
voxel is estimated and the Cp(t) measured from the superior 
sagittal sinus time- shifted to align with the BAT of each tis-
sue GBCA concentration- time curve. A map of scaled fitting 
error (SFE)27 was generated as an integral part of each fit-
ting procedure to assess the discrepancy between the derived 
curve and the original data and tumor voxels with an SFE 
value above 50% were excluded from the statistics. In all 
cases to confirm the acceptance of the use of SFE > 50% for 
excluding outlier tumor voxels, visual inspection of derived 
SFE and kinetic parameter maps (before and after exclusion 
of voxels with SFE > 50%) was performed.
2.5 | Computer simulation to evaluate the 
LEGATOS method
Dual injection DTR MRI data obtained from a patient with 
a sporadic VS imaged at 3T was used as the base for the 
computer simulation.20 HS resolution parameter estimates 
for Ktrans, vp, ve, and bolus arrival time (t0), derived from 
the LEGATOS analysis were used as the “true” values for 
simulation of a 4D FDHS GBCA concentration volume. 
The combined low- dose Cp(t) curve used as a VIF for the in 
vivo LEGATOS analysis (Figure 3A) was time- shifted and 
summed to generate a full- dose, HT resolution VIF for use in 
the simulation of tissue enhancement curves (Figure 3B). The 
simulated tissue voxel concentration- time curves were then 
F I G U R E  2  Pixel- by- pixel rescaling of the HT arterial- phase of the HTHS- merged concentration- time curve to resemble the supposed “true” 
high- spatial resolution one. Panels (A) and (B) show 2 representative pixels from the tissue GBCA concentration- time curve in a VS imaged at 3T. 
The left column represents the HTHS- merged concentration- time curve in each pixel and the right column shows the rescaling of the HT arterial- 
phase to achieve a smooth concatenation with the later parenchymal HS phase. Ratiocalib is used to rescale the initial Ct- HT(t) for each pixel, so that 
the Ct- HT(t) and Ct- HS(t) are concatenated, although maintaining the shape of the first- pass Ct- HT(t) curve. Ct- HT(t) is the HTaligned arterial phase GBCA 
concentration- time curve; Ct- HS(t) is the parenchymal HS GBCA concentration- time curve; ratiocalib = ratio of the mean concentration of several HS 
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resampled with a temporal interval of 10- s to resemble the in 
vivo acquired FDHS- DCE data set.
Quantitative image comparisons between the in vivo ac-
quired and the simulated 4D FDHS concentration volumes 
were performed using the structural similarity index.28 The 
mean structural similarity index values between 2 images were 
calculated using the same slice level within the 2 volumes. The 
simulated FDHS- DCE data set was then combined with the 
in vivo LDHT data set to construct a HTHS- merged 4D con-
centration volume as described in key step I. The ETM was 
then either directly fitted to the tissue GBCA concentration- 
time curves of this 4D HTHS- merged concentration volume 
(HTHS- merged method), or undertaken following initial HT 
concentration- time curve rescaling (the LEGATOS method), 
yielding “measured” Ktrans, vp, ve, and t0 maps.
2.6 | Tissue analysis
Tissues from 15 sporadic VS were analyzed. Ethical ap-
proval was obtained for tissue analyses (REC reference 15/
NW/0429 and 19/NS/0167). Serial 5- µm sections were cut 
from each paraffin block and stained with hematoxylin and 
eosin (H&E) and immunoperoxidase immunohistochemis-
try (IHC). Tissue sections were assessed for cell density 
(H&E), microvessel surface area (CD31) and vascular 
permeability (fibrinogen) using immunoperoxidase IHC. 
Detailed protocols are described in Supporting Information 
Methods.
2.7 | Statistical analysis
Results from the computer simulation were used to quanti-
tatively evaluate the LEGATOS method. The percentage de-
viation (PD) of the “measured” values from the “true” values 
were calculated, where PD = (measured − true)/true. Pixel- by- 
pixel calculation of PD within the 3D tumor region- of- interest 
for the patient was applied onto each of the 4 parametric maps 
derived using either the LEGATOS or the HTHS- merged 
method. Tumor mean and SD of the PD values were generated 
and compared between the 2 analysis approaches.
F I G U R E  3  Computer simulations to evaluate the LEGATOS method. Panels (A)- (D) demonstrate simulation of dual injection DCE (DICE) 
data. (A) Combined low- dose (LD) vascular input function (VIF) used for the in vivo LEGATOS analysis. The VIF shown was derived from a 
71- year- old patient with a left- sided, sporadic VS who underwent dual injection (3 mL and 9.4 mL of GBCA, respectively), DTR DCE MRI at 
3T. (B) Reconstructed VIF used for the full- dose high- spatial resolution (FDHS) DCE data simulation. This VIF was derived by time- shifting and 
adding 3 of the low- dose VIFs shown in panel A (The small panel with a time window of 40 s in the upper- right corner of the graph demonstrates 
more details of the time- shifted VIF addition). (C) Tissue uptake curves simulated using either the in vivo low- dose VIF shown in panel A (solid 
curve) or simulated using the reconstructed full- dose VIF show in panel B and rescaled with the dose ratio (dashed curve). Concentration- time 
curves were simulated using Ktrans = 0.03 min−1, ve = 0.6, and vp = 0.03. The small panel with a time window of 100 s gives more details of 
the comparison. (D) Three representative slices from a time frame (t = 40 s) of the simulated 4D FDHS DCE images (top row), compared with 
matched imaging from the in vivo 4D FDHS data (bottom row)
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For the in vivo study, mean tumor Ktrans and vp estimates 
derived from the 13 patients with GBM using either the 
LEGATOS approach or native LDHT data sets alone were 
compared using linear regression. For the 15 resected spo-
radic VS the inter- tumor correlation between DCE- MRI 
derived parameter estimates (Ktrans, vp, and ve) and tissue- 
derived metrics (H&E cell density and CD31 microvessel 
surface area) are reported as Pearson’s product moment cor-
relation coefficient (r) or Spearman’s ρ in the case of nonlin-
ear associations.
3 |  RESULTS
3.1 | Computer simulation
The combined low- dose VIF used for the in vivo LEGATOS 
analysis and the reconstructed full- dose VIF used for the 
FDHS 4D DCE volume simulations are shown in Figure 
3A,B, respectively. A close similarity between the parenchy-
mal tissue phase (t > 40 s) of the simulated low- dose GBCA 
concentration- time curves and the parenchymal phase of the 
simulated full- dose curves rescaled by the dose ratio was 
demonstrated (Figure 3C). This result supported the assump-
tion that the LDHT and FDHS 4D concentration volumes can 
be merged through concatenation of the LDHT initial phase 
with later phases of the dose- calibrated FDHS 4D concentra-
tion volumes. A high similarity between the simulated and the 
in vivo acquired 4D FDHS DCE dynamic images was seen 
(Figure 3D) and the mean structural similarity index between 
the in vivo and the simulated 4D FDHS concentration vol-
ume was 0.998 ± 0.001 (n = 35 slices, range = 0.996- 0.999).
Representative voxel fits of the in vivo acquired LDHT 
DCE- MRI data obtained from the patient imaged at 3T are 
shown in Supporting Information Figure S2 and demonstrate 
that when using the ETM, there is a good fit between the 
F I G U R E  4  Comparison of kinetic parameter maps derived from computer- simulated dual injection DCE (DICE) data with the “true” in vivo 
parameter maps. The left- hand column (in vivo- LEGATOS) displays the LEGATOS- derived kinetic parameter maps (Ktrans, vp, and ve) from the 
sporadic vestibular schwannoma (VS) patient DCE data displayed in Figure 3D, which were used as the “true” parameter values for DCE data 
simulation. The middle and right- hand column display the “measured” kinetic maps derived from analysis of the computer- simulated DICE data 
with either the LEGATOS (Simu- LEGATOS) or the HTHS- merged method (Simu- merge), respectively. Direct fitting of the simulated HTHS- 
merged data, without prior LEGATOS reconstruction produced a vp map with comparatively less spatial detail (short arrow). K
trans and ve maps 
derived directly from the simulated DICE data with the HTHS- merged method also demonstrated vessel contamination adjacent to the vestibular 
schwannoma on the left side (long arrow), an effect not seen in the LEGATOS derived images
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scaled VIF and the early phase data of both tumor and normal 
appearing grey and white matter voxels. LEGATOS analysis 
of both the in vivo acquired and the computer simulated data 
produced highly comparable kinetic parameter maps (Figure 
4). Tumoral vascular heterogeneity was clearly evident on the 
LEGATOS vp maps derived using both the in vivo acquired 
and the computer simulated data but direct fitting of the sim-
ulated HTHS- merged data without prior LEGATOS recon-
struction produced a vp map with comparatively less spatial 
detail. The accuracy of kinetic parameter estimates was im-
proved through use of the LEGATOS method compared to 
direct fitting of the simulated HTHS- merged data (vp: mean 
PD −1.4% ± 29.8% vs. 13.9% ± 180%, P = .05; ve: mean PD 
0.8% ± 13.5% vs. 11.7% ± 23.8%, P < .001; Ktrans; mean PD 
7.2% ± 12.3% vs. 8.8% ± 78.4%, P > .05).
3.2 | In vivo evaluation
For the 17 patients with VS and 13 patients with GBM na-
tive tumor R10 estimates obtained from the VFA acquisitions 
before the LDHT DCE series are given in Table 1.
Comparative kinetic parameter maps from a patient with 
NF2 and bilateral VS imaged using the dual injection DTR 
protocol are shown in Figure 5A alongside fits of representa-
tive vessel voxel GBCA concentration- time curves obtained 
using each method. Compared to the use of native LDHT data 
sets the LEGATOS method offered superior visualization of 
small lesions and intratumoral heterogeneity in derived Ktrans 
and vp maps. The DICE- FDHS method also offered superior 
spatial resolution but because of undersampling of the first- 
pass bolus in each pixel- enhancing curve, derived Ktrans and 
vp maps suffered from large vessel contamination and lack of 
vessel contrast, respectively, features not seen in the LDHT- 
or LEGATOS- derived maps. As shown in Figure 5B, whereas 
the DICE- FDHS method demonstrates poor discrimination 
between plasma volume and vascular leakage effects giving 
a very high value of Ktrans (=1.1 min−1) and low value of 
vp (=0.04) within the vessel, voxel fits of the native LDHT, 
HTHS- merged, and LEGATOS concentration- time curves 
produced lower Ktrans and higher vp values, respectively.
Representative tumor maps of Ktrans and vp in 2 patients 
with glioblastoma are shown in Figure 6 and Supporting 
Information Figure S3. Similar to the findings in VS, 
LEGATOS permitted superior visualization of microvascular 
heterogeneity in the contrast enhancing tumor edge compared 
to maps derived from the LDHT data sets alone. Estimates of 
mean tumor Ktrans and vp derived from the contrast enhanc-
ing tumor region of the 13 imaged glioblastoma are shown 
in Figure 6C and demonstrate the strong correlation between 
Ktrans (R2 = 0.88, P < .0001) and vp estimates (R
2 = 0.79, P < 
.0001) derived using either the LEGATOS approach or native 
LDHT data sets alone.
3.3 | Imaging and pathology analysis
The inter- tumor correlation between LEGATOS derived ki-
netic parameter estimates and tissue metrics in the 15 spo-
radic VS that underwent the dual injection DTR protocol 
are shown in Figure 7. There was a significant inverse cor-
relation between cell density and mean tumor ve (ρ = −0.69, 
P = .006, Figure 7A) and a significant positive correlation 
between CD31 % microvessel surface area with both mean 
tumor vp (r = 0.85, P = .001, Figure 7B) and mean tumor 
Ktrans (r = 0.71, P = .003, Figure 7C).
Representative imaging and tissue from a patient with a 
sporadic VS imaged at 1.5T is shown in Figure 8. Compared 
to use of the native LDHT data sets, the LEGATOS recon-
struction method permitted better characterization of spa-
tial heterogeneity in cell density and microvascular metrics 
across the tumor volume.
4 |  DISCUSSION
We have described LEGATOS: a novel DTR DCE- MRI pro-
cessing approach for deriving accurate, HS resolution, and 
whole- brain coverage kinetic parameter maps. Data from 
computer simulations and in vivo imaging demonstrated that 
kinetic parameters derived using LEGATOS provided su-
perior discrimination of plasma volume and vascular leak-
age effects compared to other HS resolution approaches. 
Comparison with matched tumor tissue demonstrated that 
LEGATOS derived microvascular parameters accurately 




Native R10 before LDHT 
DCE series (s−1)
Sporadic VS 15 1.5 0.68 ± 0.03
Sporadic VS 1 3 0.48
NF2- related VS 1 1.5 0.62
GBM 13 1.5 0.74 ± 0.12
Abbreviations: GBM, glioblastoma; VS, vestibular schwannoma.
T A B L E  1  Tumor mean native R10 
estimated from the VFA acquisitions for the 
17 patients with VS and 13 patients with 
GBM
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area and cell density and permitted better evaluation of in-
tratumoral heterogeneity in these tissue metrics compared to 
HT data alone.
Previous attempts to derive HS kinetic parameters from 
DTR DCE- MRI such as the DICE- FDHS method17 showed 
significant covariate fitting errors in derived parameter maps 
because of the low- temporal resolution of the sampled tis-
sue uptake curves. Our strategy overcomes this limitation 
by first merging the separately acquired HT (low- spatial) 
and HS (low- temporal) DCE- MRI data sets into a merged 
4D GBCA concentration- time course, and second rescaling 
the HT arterial phase of this HTHS- merged concentration- 
time course to match the “true” HS one, before subsequent 
kinetic analysis. We hypothesized that HT sampling of the 
initial part of the tissue uptake curves would address fitting 
errors induced by temporal jitter uncertainty (uncertainty in 
time alignment of the arterial input function and tissue uptake 
curves)29 and undersampling at the bolus peak. Our acquired 
data supported this with the LEGATOS derived parameter 
maps demonstrating superior separation of plasma volume 
and vascular leakage- based changes in the tissue GBCA 
concentration- time course.
F I G U R E  5  Kinetic parameter maps from a neurofibromatosis type- 2 patient imaged using a dual injection, dual- temporal resolution protocol. 
(A) Ktrans and vp maps obtained from dual injection DCE (DICE) MRI at 1.5T are shown. Note the large right- sided VS and multiple supra- and 
infra- tentorial meningiomas in this patient. Maps derived using the native low- dose high- temporal resolution tissue concentration- time curves 
(LDHT), the native full- dose high- spatial resolution tissue concentration- time curves (DICE- FDHS method), the HTHS- merged data and the 
LEGATOS reconstructed data are shown. Although the LDHT derived Ktrans map appears free of large vessel contamination, the small tuberculum 
sellae meningioma (long arrow) is difficult to visualize. The DICE- FDHS derived maps better demonstrate this meningioma and intratumoral 
heterogeneity within the VS but show considerable large vessel contamination (short arrow). The degree of large vessel contamination is reduced in 
the HTHS- merged data and almost absent in the LEGATOS derived Ktrans map. Relative to the HTHS- merged data, the LEGATOS map displayed 
greater spatial detail in the derived vp map. (B) Fits of representative vessel voxel GBCA concentration- time curves with the ETM. Fits obtained 
using each method shown. The DICE- FDHS method demonstrate poor discrimination of plasma volume and vascular leakage effects in the vessel 
GBCA concentration- time curve giving a high value of Ktrans (=1.1 min−1) and low value of vp (=0.04) within the vessel. Voxel fits of the native 
LDHT, HTHS- merged, and LEGATOS concentration- time curves produced lower Ktrans and higher vp values, respectively
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Previous in vivo studies in sporadic VS have demonstrated 
that kinetic parameter estimates derived through use of the 
ETM with low- spatial, HT resolution DCE- MRI accurately 
reflect inter- tumor differences in tissue vascularity metrics 
and correlate with differences in macrophage content and 
tumor growth rate.5,30 However, the inherent low- spatial res-
olution in derived parameter maps limited accurate assess-
ment of intratumoral heterogeneity, especially within smaller 
lesions. In the present study we demonstrated that HS resolu-
tion LEGATOS derived microvascular parameters permitted 
better evaluation of intratumoral heterogeneity in microvessel 
area and cell density compared to HT data alone and accu-
rately differentiated inter- tumor differences in these tissue 
parameters. The LEGATOS- derived mean tumor ve showed 
an inverse correlation with cell density, and both the mean 
tumor vp and mean tumor K
trans showed a positive correlation 
with CD31 % microvessel surface area. Although a limitation 
of any non- invasive imaging technique such as DCE- MRI is 
that the true in vivo tissue perfusion parameters are unknown 
and can only be extrapolated from architectural features de-
tectable on ex vivo tissue specimens such as microvessel 
density and microvessel surface area, the correlation between 
CD31 and both DCE- MRI derived vp and K
trans has been pre-
viously reported in human vessel wall studies.31- 33
Previous authors have attempted to achieve high spa-
tiotemporal resolution in DCE- MRI through the use of ad-
vanced time resolved or “keyhole” imaging techniques34 
such as Siemens TWIST,35 Phillips 4D- TRAK36, GE’s 
F I G U R E  6  Application of the LEGATOS technique in a patient with a right temporal glioblastoma (GBM). (A) T1W post contrast image 
demonstrating a right temporal glioblastoma (GBM). Note the contrast enhancing tumor rim and the non- enhancing central necrotic core. (B) 
Kinetic parameter maps of the GBM shown in panel A. From left to right: parametric vp and K
trans map in axial plane; and parametric vp and K
trans 
map in coronal plane. Note the superior visualization of normal vascular anatomy and microvascular heterogeneity in the contrast enhancing tumor 
edge permitted by the LEGATOS technique compared to maps derived from the native low- dose high- temporal (LDHT) data sets. (C) Mean tumor 
Ktrans (left) and vp (right) estimates derived from the contrast enhancing tumor region of the 13 imaged GBM using the LDHT and LEGATOS 
methods. The left panel demonstrates the strong correlation between Ktrans estimates derived using the LEGATOS approach and estimates derived 
from the native LDHT data sets alone (R2 = 0.88, P < .0001). The right panel demonstrates the strong correlation between vp estimates derived 
using the LEGATOS approach and estimates derived from the native LDHT data sets alone (R2 = 0.79, P < .0001)
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TRICKS,37 and DISCO.38 Such techniques improved 
temporal resolution during data acquisition through un-
dersampling of peripheral k- space. There has also been 
growing interest in estimating kinetic parameters directly 
from undersampled k- ,t- space data without prior data re-
construction.39,40 Our dual injection DTR DCE- MRI ap-
proach, however, offers greater temporal resolution during 
image acquisition (Δt < 1.5 s) compared to many of the 
above techniques, and a distinct advantage of the presented 
LEGATOS method is that it can be retrospectively acquired 
to dual injection DTR DCE- MRI data without the need for 
peripheral k- space undersampling.
In addition to its demonstrated application with full- dose 
DTR protocols, applicability of LEGATOS with a single in-
jection low GBCA dose (fixed volume of 3 mL) interleaved 
HT and HS protocol has also been demonstrated in prelim-
inary prospective unpublished studies at our institution.21 
Although the risk of gadolinium deposition in the brain fol-
lowing administration of macrocyclic GBCA such as gad-
oterate meglumine is thought to be lower than linear agents 
and the long- term clinical sequelae of such deposition is cur-
rently unknown12,13 the ability to derive HS resolution kinetic 
parameter data following a low- dose administration may still 
have considerable clinical relevance, especially in patients 
F I G U R E  7  Comparison of LEGATOS derived parameters from the dual injection DTR DCE- MRI data sets against tissue derived parameters. 
(A) Inter- tumor scatterplot comparison of mean tumor ve estimates against hematoxylin and eosin (H&E) cell density (nuclei/ x20HPF). (B) Inter- 
tumor scatterplot analysis of mean vascular fraction (vp) against mean CD31 % microvessel surface area (SA). (C) Inter- tumor scatterplot analysis 
of mean tumor Ktrans (min−1) against mean CD31 % microvessel surface area (SA). (D) Representative LEGATOS derived kinetic parameter maps 
from a patient with a growing highly vascular VS (top row) and a less vascular static VS (bottom row) are shown. From left to right: T1W post 
contrast image; parametric ve map; parametric K
trans map, and parametric vp map. (E- F) H&E stained section (left, HE- x20HPF) and immunostain 
(right, CD31, brown; immunoperoxidase – x20HPF) from the growing (top row) and static (bottom row) VS shown in panel D. Note the lower cell 
density (HE) and higher microvessel density (CD31) in the growing VS in keeping with the imaging findings. Data from 15 tumors (sporadic VS) 
shown. **Pearson’s product moment correlation coefficient (r) reported or Spearman’s ρ in the case of non- linear association between variables
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undergoing repeated GBCA exposures and in clinical trials 
where microvascular parameters are felt to be relevant out-
come markers such as trials of antiangiogenic treatment.41 
Further studies incorporating the LEGATOS technique and 
low GBCA dose acquisition protocols are, however, required 
to better evaluate the effect of this low- dose approach on 
image contrast- to- noise, and the accuracy of kinetic parame-
ters derived using this technique.21
The proposed LEGATOS method relies on the assump-
tion that in each pixel of the HTHS- merged 4D concentra-
tion volume generated in key step I, the supposed “true” HS 
resolution arterial phase has the same shape as the observed 
HTaligned arterial phase, and therefore, can be obtained by res-
caling the HTaligned arterial phase to achieve a smooth con-
nection with the HS parenchymal phase. The ETM further 
assumes that the arterial phase of each enhanced tissue pixel 
curve is the initial plasma concentration curve scaled by 
vp. However, the above assumption may not be met if the 
HTaligned and “true” HS concentration curves display signif-
icant differences in the bolus mean transit time and/or in the 
amount of GBCA leakage. In this case, reconstruction of the 
initial HT contrast agent concentration curve using a single 
concentration ratio is not suitable and more complex adjust-
ment may be required.
The ETM has been adopted in this study as previous 
application of this model with low- spatial resolution HT 
data sets derived from DTR DCE- MRI was found to give 
both tissue- validated and clinically relevant kinetic param-
eter estimates.4,5,30 Recent studies have also shown through 
a model selection process using the Akaike information 
F I G U R E  8  Evaluation of heterogeneity in tumor microvascular metrics using the LEGATOS technique. (A) T1W post contrast image 
demonstrating growing left sided VS, note the heterogenous enhancement within the tumor. Scale bar = 10 mm. (B) Kinetic parameter maps (ve, 
Ktrans, and vp) of the VS shown in panel A derived using dual injection DTR DCE- MRI. Parameter maps derived from the native LDHT data sets 
(top row, LDHT) and the LEGATOS reconstructed data sets (bottom row, LEGATOS) are shown. Note the spatial heterogeneity in LEGATOS 
derived ve, K
trans, and vp values across the imaged tumor slice. (C) Hematoxylin and eosin (H&E) stained section (top, HE- whole mount) and 
immunostains (middle, fibrinogen, brown; bottom, CD31, brown; immunoperoxidase— whole mount) from the tumor shown in panel A/B 
demonstrate heterogeneity in cell density (H&E), perivascular leak (fibrinogen) and microvessel density (CD31) across the tumor section. (D and 
E) Higher magnification images of the areas framed in the whole mount demonstrating regions of high (D) and low (E) cell density (HE, ×20 HPF), 
perivascular leak (fibrinogen, immunoperoxidase ×10 HPF) and microvessel density (CD31, immunoperoxidase × 10 HPF)
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criteria, that the ETM was one of the optimal models in 
pharmacokinetic analysis of DCE- MRI data in brain tu-
mors42 and papillary thyroid carcinoma.43 One limitation 
of the ETM is that the derived parameter Ktrans is a hy-
brid parameter reflecting both capillary blood flow and 
permeability effects,44,45 and future studies incorporating 
the high spatiotemporal resolution DCE data provided by 
the LEGATOS method and other DCE- MRI models, which 
seek to further separate out such effects should, therefore, 
be undertaken.
5 |  CONCLUSION
We developed a novel DTR technique called LEGATOS 
to generate HS resolution kinetic parametric maps with an 
accuracy normally only obtainable with HT (Δt < 1.5 s), 
low- spatial resolution DCE- MRI. The accuracy of kinetic 
parameters estimated using this new technique outperformed 
previous DTR methods for deriving HS resolution param-
eter maps and analysis of tissue from VS investigated with 
LEGATOS validated our approach. Clinical application of 
this modality and its application with low GBCA dose DCE- 
MRI protocols require further studies.
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FIGURE S1 Vascular input function (VIF) estimation from 
the middle cerebral artery (MCA), the internal carotid artery 
(ICA), and the superior sagittal sinus (SSS). Plasma GBCA 
concentration curves Cp(t) measured from the horizontal 
segment of the MCA; the vertical segment of the internal 
carotid artery (ICA; ie, carotid syphon); and the vertical seg-
ment of the (SSS) following a bolus injection of 0.02 mmol/
kg of macrocyclic GBCA (gadoterate meglumine; Dotarem, 
Guerbet S.A). The first- pass data are fitted using a γ vari-
ate function, which excludes GBCA bolus recirculation. 
The first- pass bolus kinetic parameters from each derived 
VIF, including the contrast bolus arrival time (BAT), the full 
width at half maximum (FWHM) and peak height (peak), 
are shown. Although the BAT in the SSS is 3.4 s later than 
the ICA, the VIF measured from the SSS has a higher and 
narrower peak than those measured from the corresponding 
arterial vessels. Reduced partial volume effects when per-
forming VIF measurement within the wider SSS, and may 
in part explain the higher and narrower peak observed. In 
addition, reduced “in flow” effects because of both lower 
blood velocity in the SSS and a longer transit time within 
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the imaging volume for measured blood within the SSS (and 
thereby more received RF pulses) compared to blood within 
the ICA or MCA, which may also contribute to the ob-
served differences. All images and VIF estimates obtained 
from a patient with a sporadic VS imaged at 1.5T. GBCA = 
gadolinium- based- contrast agent
FIGURE S2 GBCA concentration— (A) time curves from 
representative voxels within tumor tissue; (B) normal- 
appearing grey matter (GM); and (C) normal appearing white 
matter (WM). Voxel curves derived from low- dose high- 
temporal (LDHT) DCE- MRI data in a sporadic VS patient 
imaged at 3T. Fits obtained using the extended Tofts model 
(ETM) for each voxel curve are shown on the included fig-
ures (solid line) along with the derived parameter estimates. 
Normal- appearing GM or WM have a Ktrans too low to be 
measured using the ETM, giving zero Ktrans for both the GM 
and WM voxels. The above curves demonstrate that when 
using the ETM, there is a good fit between the scaled VIF and 
the early phase data of tumor, or normal- appearing GM or 
WM voxels and that the degree of dispersion in the tissue or 
widening of the concentration- time curve in each tissue voxel 
during the first pass is consistent within each patient. GBCA 
= gadolinium- based- contrast agent
FIGURE S3 Application of the LEGATOS technique in a 
patient with left parietal glioblastoma (GBM). (A) T1W post 
contrast image demonstrating a left parietal glioblastoma 
(GBM). (B) Kinetic parameter maps of the GBM shown in 
panel A. From left to right: parametric Ktrans map, parametric 
vp map and magnification images demonstrating voxel- wise 
heterogeneity in Ktrans and vp across the tumor. Parameter 
maps derived from the native low- dose high- temporal reso-
lution data sets (top row, LDHT) and the LEGATOS recon-
structed data sets (bottom row, LEGATOS) are shown
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